These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15482184)

  • 1. Lamivudine for chronic hepatitis B.
    Leung N
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):173-80. PubMed ID: 15482184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
    Da Silva LC; Pinho JR; Sitnik R; Da Fonseca LE; Carrilho FJ
    J Gastroenterol; 2001 Jul; 36(7):476-85. PubMed ID: 11480792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon and lamivudine for hepatitis B.
    Assy NN; Hussein O
    N Engl J Med; 2004 Dec; 351(27):2879; author reply 2879. PubMed ID: 15625344
    [No Abstract]   [Full Text] [Related]  

  • 4. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature.
    Ben-Ari Z; Mor E; Tur-Kaspa R
    J Intern Med; 2003 May; 253(5):544-52. PubMed ID: 12702032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adefovir dipivoxil in chronic hepatitis B infection.
    Yuen MF; Lai CL
    Expert Opin Pharmacother; 2004 Nov; 5(11):2361-7. PubMed ID: 15500383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.
    Ni YH; Huang FC; Wu TC; Kong MS; Jeng YM; Chen PJ; Tsuei DJ; Chen HL; Hsu HY; Chang MH
    Pediatr Int; 2005 Aug; 47(4):372-7. PubMed ID: 16091071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection.
    Zoulim F
    Drug Saf; 2002; 25(7):497-510. PubMed ID: 12093308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine for the treatment of chronic hepatitis B.
    Sokal E
    Expert Opin Pharmacother; 2002 Mar; 3(3):329-39. PubMed ID: 11866682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy.
    Zöllner B; Schäfer P; Feucht HH; Schröter M; Petersen J; Laufs R
    J Med Virol; 2001 Dec; 65(4):659-63. PubMed ID: 11745928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current pharmacotherapy for the treatment of chronic hepatitis B.
    Lagget M; Rizzetto M
    Expert Opin Pharmacother; 2003 Oct; 4(10):1821-7. PubMed ID: 14521491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
    Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
    Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
    Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
    Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
    Yu MM; Jiang Q; Ji Y; Wu KH; Ju LL; Tang X; Yang YF
    J Clin Virol; 2014 Sep; 61(1):55-60. PubMed ID: 24994007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lamivudine treatment for hepatitis B].
    Lamivudine Clincal Practice Group
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis.
    Njei B; Gupta N; Ewelukwa O; Ditah I; Foma M; Lim JK
    Liver Int; 2016 May; 36(5):634-41. PubMed ID: 26352650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.